X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1508) 1508
Publication (215) 215
Book Chapter (25) 25
Book Review (9) 9
Conference Proceeding (4) 4
Dissertation (2) 2
Magazine Article (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
telaprevir (1485) 1485
index medicus (1031) 1031
humans (998) 998
boceprevir (701) 701
hepatitis c (690) 690
ribavirin (649) 649
hepatitis c virus (611) 611
hepatitis c, chronic - drug therapy (605) 605
antiviral agents - therapeutic use (579) 579
male (535) 535
gastroenterology & hepatology (530) 530
female (504) 504
hepacivirus - genetics (488) 488
middle aged (466) 466
drug therapy, combination (422) 422
genotype (409) 409
interferon (372) 372
adult (356) 356
treatment outcome (355) 355
ribavirin - therapeutic use (340) 340
peginterferon (325) 325
hepacivirus - drug effects (303) 303
protease inhibitors (301) 301
interferon-alpha - therapeutic use (287) 287
aged (276) 276
virus-infection (272) 272
hepatitis (264) 264
hepatitis c, chronic - virology (259) 259
plus ribavirin (255) 255
pharmacology & pharmacy (253) 253
infectious diseases (248) 248
therapy (246) 246
antiviral agents - administration & dosage (243) 243
antiviral agents - adverse effects (242) 242
oligopeptides - therapeutic use (242) 242
virology (239) 239
hepatitis c - drug therapy (237) 237
antiviral agents (233) 233
polyethylene glycols - therapeutic use (231) 231
proline - analogs & derivatives (223) 223
pegylated interferon (219) 219
biological response modifiers (218) 218
hcv (217) 217
genotype 1 infection (211) 211
health aspects (211) 211
sustained virological response (209) 209
infection (207) 207
care and treatment (194) 194
proteases (184) 184
drug therapy (179) 179
recombinant proteins - therapeutic use (178) 178
genetic aspects (168) 168
analysis (166) 166
sofosbuvir (163) 163
chronic hepatitis-c (160) 160
ribavirin - administration & dosage (160) 160
gastroenterology and hepatology (157) 157
antiviral agents - pharmacology (152) 152
chronic hepatitis c (152) 152
virus diseases (152) 152
viral load (150) 150
proline - therapeutic use (145) 145
protease inhibitor (134) 134
cirrhosis (130) 130
interferon-alpha - administration & dosage (130) 130
protease inhibitors - therapeutic use (127) 127
young adult (127) 127
oligopeptides - adverse effects (123) 123
rna, viral - blood (123) 123
liver cirrhosis (122) 122
peginterferon alpha-2a (122) 122
simeprevir (121) 121
genotype 1 (120) 120
triple therapy (120) 120
combination (119) 119
hepatitis c - virology (117) 117
liver (117) 117
polyethylene glycols - administration & dosage (116) 116
hepacivirus - isolation & purification (112) 112
microbiology (112) 112
viral nonstructural proteins - antagonists & inhibitors (112) 112
hepatology (110) 110
hiv (108) 108
combination therapy (106) 106
drug resistance, viral (106) 106
treatment-naive patients (106) 106
medicine, general & internal (104) 104
genotype & phenotype (103) 103
oligopeptides - administration & dosage (103) 103
antiviral therapy (100) 100
anemia (98) 98
resistance (98) 98
ribavirin - adverse effects (98) 98
infections (96) 96
virus (96) 96
hepacivirus - classification (95) 95
viral nonstructural proteins - genetics (95) 95
recombinant proteins - administration & dosage (93) 93
rna (93) 93
abridged index medicus (91) 91
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1403) 1403
Spanish (38) 38
Hungarian (20) 20
German (19) 19
French (17) 17
Japanese (16) 16
Russian (7) 7
Czech (5) 5
Turkish (3) 3
Korean (2) 2
Italian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Infectious Diseases, ISSN 1058-4838, 12/2014, Volume 59, Issue 12, pp. 1777 - 1778
Journal Article
Hepatology, ISSN 0270-9139, 06/2013, Volume 57, Issue 6, pp. 2143 - 2154
Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.... 
NONRESPONSE | TELAPREVIR | THERAPY | HEPATITIS-C VIRUS | PEGINTERFERON ALPHA-2A | BI 201335 | PHARMACOKINETICS | PROTEASE INHIBITOR BI201335 | 1 INFECTION | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 60, Issue 1, pp. 78 - 86
Background & Aims: Protease inhibitors (PI) with peginterferon/ ribavirin have significantly improved SVR rates in HCV G1 patients. Their use to treat HCV... 
Boceprevir | Protease inhibitors | Early virological response | HCV recurrence | Sustained virological response | Telaprevir | Drug-drug interaction | Liver transplantation
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 9, pp. 1525 - 1529
To compare the rate of treatment discontinuation due to adverse events for telaprevir-based triple (T/PR) and pegylated interferon-alfa-2b and ribavirin (PR)... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1889 - 1898
Journal Article
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017
In this study, a nationwide database was used to identify the risk factors for treatment discontinuation due to adverse events during telaprevir,... 
regional differences | ribavirin | telaprevir | nationwide database | hepatitis C | interferon
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 3, pp. 211 - 221
Journal Article